Revolution Medicines Warrant (RVMDW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RVMDW SEC filings page.
Revolution Medicines, Inc. Warrant (RVMDW) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a development-stage business where research spending is expanding faster than internally generated cash, increasing financing dependence.
Operating cash flow was-$897.7M against a net loss of$1.131B in FY2025, so the loss was accompanied by substantial cash outflow rather than being mainly an accounting-only result. Cash conversion remains weak because free cash flow was-$913.7M , only slightly below operating cash flow, leaving little evidence that investment spending explains most of the deficit.
Research investment has become the dominant operating commitment: R&D reached
The balance-sheet posture weakened despite no reported long-term debt: liabilities expanded while equity contracted, and the debt-to-equity ratio was 0.0x. This points to greater reliance on non-debt obligations or other balance-sheet claims to support a business consuming substantial cash.
Financial Health Signals
Revolution Medicines, Inc. Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Revolution Medicines, Inc. Warrant passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Revolution Medicines, Inc. Warrant reported a net loss of $1.1B while operations used $897.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Revolution Medicines, Inc. Warrant reported an operating loss of $1.2B against $24.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Revolution Medicines, Inc. Warrant's EBITDA was -$503.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Revolution Medicines, Inc. Warrant reported a net loss of $644.4M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Revolution Medicines, Inc. Warrant earned -$3.06 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Revolution Medicines, Inc. Warrant recorded an outflow of $389.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Revolution Medicines, Inc. Warrant held $815.4M in cash against $487.4M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Revolution Medicines, Inc. Warrant's quarterly ROE was -24.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 11.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Revolution Medicines, Inc. Warrant invested $394.9M in research and development in Q2 2026. This represents an increase of 76.2% from the same quarter a year earlier. Against the prior quarter it is up 14.8%.
Revolution Medicines, Inc. Warrant invested $2.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 69.3% from the same quarter a year earlier. Against the prior quarter it is up 48.6%.
Not reported for Q2 2026.
RVMDW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| R&D Expenses | $394.9M+76.2% | $344.0M+67.2% | N/A | $262.5M+73.0% | $224.1M+66.1% | $205.7M+74.3% | N/A | $151.8M+40.9% |
| SG&A Expenses | $110.2M+171.6% | $101.3M+189.2% | N/A | $52.8M+120.2% | $40.6M+86.9% | $35.0M+53.3% | N/A | $24.0M+54.5% |
| Operating Income | -$505.1Mn/m | -$445.2Mn/m | N/A | -$315.3Mn/m | -$264.7Mn/m | -$240.8Mn/m | N/A | -$175.7Mn/m |
| EBITDA | -$503.0Mn/m | -$442.9Mn/m | N/A | -$313.0Mn/m | -$262.7Mn/m | -$239.1Mn/m | N/A | -$173.8Mn/m |
| Interest Expense | $23.8M+2642.9% | $12.2Mn/m | N/A | $11.4Mn/m | $867K | $0 | N/A | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Net Income | -$644.4Mn/m | -$453.8Mn/m | N/A | -$305.2Mn/m | -$247.8Mn/m | -$213.4Mn/m | N/A | -$156.3Mn/m |
| EPS (Basic) | -$3.06n/m | -$2.29n/m | -$1.89n/m | -$1.61n/m | -$1.31n/m | -$1.13n/m | -$1.13n/m | -$0.94 |
| EPS (Diluted) | -$3.06n/m | -$2.29n/m | -$1.89n/m | -$1.61n/m | -$1.31n/m | -$1.13n/m | -$1.13n/m | -$0.94 |
| Diluted Shares (Avg) | 211M+11.8% | 198M+5.3% | N/A | 189M+13.4% | 189M+14.2% | 188M+14.2% | N/A | 167M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
RVMDW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.3B+77.9% | $2.3B-4.7% | $2.4B-8.0% | $2.3B+27.7% | $2.4B+34.3% | $2.4B+23.9% | $2.6B+24.1% | $1.8B+79.1% |
| Current Assets | $4.0B+85.1% | $2.0B-7.8% | $2.1B-10.9% | $2.0B+25.2% | $2.2B+34.0% | $2.1B+23.4% | $2.3B+23.9% | $1.6B+91.5% |
| Cash & Equivalents | $815.4M+102.6% | $440.9M+32.2% | $383.7M-29.3% | $217.4M+8.0% | $402.4M+46.0% | $333.6M+15.6% | $543.1M-22.0% | $201.3M-43.8% |
| Short-Term Investments | $3.1B+80.0% | $1.5B-17.1% | $1.6B-6.0% | $1.7B+27.1% | $1.7B+31.9% | $1.8B+25.0% | $1.7B+51.0% | $1.3B+196.4% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $14.6M0.0% | $14.6M0.0% | $14.6M0.0% | $14.6M0.0% | $14.6M0.0% | $14.6M0.0% | $14.6M0.0% | $14.6M0.0% |
| Total Liabilities | $1.7B+204.3% | $753.8M+162.5% | $723.2M+146.7% | $655.0M+233.0% | $564.2M+197.6% | $287.2M+57.0% | $293.1M+24.5% | $196.7M+34.0% |
| Current Liabilities | $354.1M+91.9% | $289.6M+82.6% | $290.4M+77.2% | $245.6M+121.6% | $184.5M+75.2% | $158.6M+69.2% | $163.9M+13.9% | $110.9M+29.6% |
| Non-Current Liabilities | $1.4B+259.0% | $464.2M+261.0% | $432.8M+235.0% | $409.4M+377.0% | $379.7M+350.6% | $128.6M+44.2% | $129.2M+40.9% | $85.8M+40.2% |
| Long-Term Debt | $487.4M | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.6B+39.7% | $1.5B-27.8% | $1.6B-28.0% | $1.6B+2.0% | $1.9B+15.2% | $2.1B+20.4% | $2.3B+24.0% | $1.6B+87.0% |
| Retained Earnings | -$4.0Bn/m | -$3.3Bn/m | -$2.9Bn/m | -$2.5Bn/m | -$2.2Bn/m | -$2.0Bn/m | -$1.7Bn/m | -$1.5Bn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
RVMDW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$387.3Mn/m | -$354.2Mn/m | -$274.2Mn/m | -$207.3Mn/m | -$221.8Mn/m | -$194.4Mn/m | -$138.3Mn/m | -$130.4Mn/m |
| Depreciation & Amortization | $2.1M+5.0% | $2.3M+38.7% | $2.3M+30.7% | $2.3M+21.1% | $2.0M+5.3% | $1.7M+9.9% | $1.7M | $1.9M+18.8% |
| Stock-Based Compensation | $67.0M+132.4% | $87.3M+248.0% | N/A | $30.8M+48.2% | $28.8M+45.8% | $25.1M+54.8% | N/A | $20.8M+52.0% |
| Capital Expenditures | $2.3M-69.3% | $1.5M-52.9% | $1.9M+57.5% | $3.3M-4.9% | $7.5M+210.5% | $3.3M+3.1% | $1.2M-47.3% | $3.5M+38.9% |
| Free Cash Flow | -$389.6Mn/m | -$355.7Mn/m | -$276.2Mn/m | -$210.7Mn/m | -$229.2Mn/m | -$197.7Mn/m | -$139.5Mn/m | -$133.9Mn/m |
| Investing Cash Flow | -$1.7B-4939.2% | $172.6Mn/m | $74.9Mn/m | $24.8Mn/m | $34.3M-68.2% | -$15.9Mn/m | -$392.9Mn/m | -$21.5M-127.8% |
| Financing Cash Flow | $2.4B+843.4% | $238.7M+27216.2% | $365.7M-58.2% | -$1.6M-102.1% | $256.6M+3319.3% | $874K+7.9% | $873.8M+4.1% | $77.3M+7545.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RVMDW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -24.7%-11.4pp | -30.3%-20.0pp | N/A | -19.1%-9.1pp | -13.3%-5.1pp | -10.3%-3.6pp | N/A | -10.0%+3.0pp |
| Return on Assets | -14.9%-4.7pp | -20.1%-11.1pp | N/A | -13.6%-4.7pp | -10.2%-2.8pp | -9.0%-2.9pp | N/A | -8.9%+2.2pp |
| Current Ratio | 11.38-0.4x | 6.80-6.7x | 7.14-7.1x | 8.05-6.2x | 11.79-3.6x | 13.46-5.0x | 14.20+1.1x | 14.24+4.6x |
| Debt-to-Equity | 0.19 | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.66+0.4x | 0.50+0.4x | 0.44+0.3x | 0.41+0.3x | 0.30+0.2x | 0.140.0x | 0.130.0x | 0.130.0x |
| Asset Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.000.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Where Revolution Medicines, Inc. Warrant Ranks
Frequently Asked Questions
What is Revolution Medicines, Inc. Warrant's annual revenue?
Revolution Medicines, Inc. Warrant (RVMDW) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Revolution Medicines, Inc. Warrant profitable?
No, Revolution Medicines, Inc. Warrant (RVMDW) reported a net loss of $1.1B in fiscal year 2025.
What is Revolution Medicines, Inc. Warrant's EBITDA?
Revolution Medicines, Inc. Warrant (RVMDW) had EBITDA of -$1.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Revolution Medicines, Inc. Warrant have?
As of fiscal year 2025, Revolution Medicines, Inc. Warrant (RVMDW) had $383.7M in cash and equivalents against $0 in long-term debt.
What is Revolution Medicines, Inc. Warrant's return on equity (ROE)?
Revolution Medicines, Inc. Warrant (RVMDW) has a return on equity of -69.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Revolution Medicines, Inc. Warrant's free cash flow?
Revolution Medicines, Inc. Warrant (RVMDW) recorded an outflow of $913.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Revolution Medicines, Inc. Warrant's operating cash flow?
Revolution Medicines, Inc. Warrant (RVMDW) recorded an outflow of $897.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Revolution Medicines, Inc. Warrant's total assets?
Revolution Medicines, Inc. Warrant (RVMDW) had $2.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Revolution Medicines, Inc. Warrant's capital expenditures?
Revolution Medicines, Inc. Warrant (RVMDW) invested $16.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Revolution Medicines, Inc. Warrant spend on research and development?
Revolution Medicines, Inc. Warrant (RVMDW) invested $987.3M in research and development during fiscal year 2025.
What is Revolution Medicines, Inc. Warrant's current ratio?
Revolution Medicines, Inc. Warrant (RVMDW) had a current ratio of 7.14 as of fiscal year 2025, which is generally considered healthy.
What is Revolution Medicines, Inc. Warrant's debt-to-equity ratio?
Revolution Medicines, Inc. Warrant (RVMDW) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Revolution Medicines, Inc. Warrant's liabilities-to-equity ratio?
Revolution Medicines, Inc. Warrant (RVMDW) had a liabilities-to-equity ratio of 0.44 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Revolution Medicines, Inc. Warrant's return on assets (ROA)?
Revolution Medicines, Inc. Warrant (RVMDW) had a return on assets of -48.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Revolution Medicines, Inc. Warrant's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Revolution Medicines, Inc. Warrant (RVMDW) held $2.0B in cash, cash equivalents and investments, and reported an operating cash outflow of $897.7M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Revolution Medicines, Inc. Warrant's Piotroski F-Score?
Revolution Medicines, Inc. Warrant (RVMDW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Revolution Medicines, Inc. Warrant's earnings high quality?
Revolution Medicines, Inc. Warrant (RVMDW) reported a net loss of $1.1B while operations used $897.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Revolution Medicines, Inc. Warrant cover its interest payments?
Revolution Medicines, Inc. Warrant (RVMDW) reported an operating loss of $1.2B against $24.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.